Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDP-001 |
| Synonyms | |
| Therapy Description |
IDP-001 is an antibody-drug conjugate (ADC) targeting EGFR and CDCP1, which potentially inhibits growth of EGFR and CDCP-expressing tumors (Cancer Res (2025) 85 (8_Supplement_1): 2933). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDP-001 | IDP001|IDP 001 | EGFR Antibody 78 | IDP-001 is an antibody-drug conjugate (ADC) targeting EGFR and CDCP1, which potentially inhibits growth of EGFR and CDCP-expressing tumors (Cancer Res (2025) 85 (8_Supplement_1): 2933). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07602842 | Phase Ib/II | IDP-001 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | Not yet recruiting | USA | 0 |